1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.
J Clin Invest 116:288–296. 2006;
2. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139–274. 2012.
3. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
Hypertension 31:451–458. 1998;
4. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats.
Hypertension 33:232–237. 1999;
5. Qin D, Morita H, Inui K, Tayama H, Inoue Y, Yoshimura A. Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis.
J Nephrol 26:199–206. 2013;
6. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat.
J Clin Invest 98:1063–1068. 1996;
7. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Am J Physiol Heart Circ Physiol 283:H1802–H1810. 2002;
8. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Kidney Int 58:1219–1227. 2000;
9. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Am J Kidney Dis 46:45–51. 2005;
10. Zitt E, Eller K, Huber JM, et al. The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomerulonephritis.
Int J Clin Exp Pathol 4:606–615. 2011;
11. Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ. The role of aldosterone blockade in murine lupus nephritis.
Arthritis Res Ther 10:R5.2008;
12. Asai M, Monkawa T, Marumo T, et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.
Hypertens Res 27:971–978. 2004;
13. Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive renal disease.
Hum Pathol 13:314–322. 1982;
14. Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Kidney Int 91:1014–1021. 2017;
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.
Ann Intern Med 150:604–612. 2009;
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
Hypertension 41:64–68. 2003;
17. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
N Engl J Med 345:925–926. 2001;
18. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat.
Kidney Int 36:526–536. 1989;
19. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.
Hypertension 13:305–314. 1989;
20. Fogo A, Yoshida Y, Yared A, Ichikawa I. Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys.
Kidney Int 38:1068–1074. 1990;
21. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
J Clin Invest 77:1993–2000. 1986;
22. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
J Clin Invest 90:766–771. 1992;
23. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Ggroup.
N Engl J Med 329:1456–1462. 1993;
24. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial.
Lancet 352:1252–1256. 1998;
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 345:861–869. 2001;
26. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med 345:870–878. 2001;
27. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough.
Nat Clin Pract Nephrol 3:486–492. 2007;
28. Moranne O, Bakris G, Fafin C, Favre G, Pradier C, Esnault VL. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
Clin J Am Soc Nephrol 8:1694–1701. 2013;
29. Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients.
Hypertens Res 23:25–31. 2000;
30. Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
Cardiovasc Drugs Ther 9:145–149. 1995;
31. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Eur Heart J 16:Suppl N. 103–106. 1995;
32. Schrier RW. Aldosterone ‘escape’ vs ‘breakthrough’.
Nat Rev Nephrol 6:61.2010;
33. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone.
J Am Soc Nephrol 16:3306–3314. 2005;
34. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Clin J Am Soc Nephrol 1:940–951. 2006;
35. Antunes VV, Veronese FJ, Morales JV. Diagnostic accuracy of the protein/creatinine ratio in urine samples to estimate 24-h proteinuria in patients with primary glomerulopathies: a longitudinal study.
Nephrol Dial Transplant 23:2242–2246. 2008;